Suppr超能文献

靶向表观遗传蛋白的PROTACs

PROTACs Targeting Epigenetic Proteins.

作者信息

Zhang Chao, He Yuna, Sun Xiuyun, Wei Wenyi, Liu Yanlong, Rao Yu

机构信息

Changping Laboratory, Beijing 102206, China.

State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.

出版信息

Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.

Abstract

Epigenetics, a field that investigates alterations in gene function that can be inherited without changes in DNA sequence, encompasses molecular pathways such as histone variants, posttranslational modifications of amino acids, and covalent modifications of DNA bases. These pathways modulate the transformation of genotypes into specific phenotypes. Epigenetics plays a substantial role in cell growth, development, and differentiation by dynamically regulating gene transcription and ensuring genomic stability. This regulation is carried out by three key players: writers, readers, and erasers. In recent years, epigenetic proteins have played a crucial role in epigenetic regulation and have gradually become important targets in drug research and development. Targeted therapy is an essential strategy; however, the effectiveness of targeted drugs is often limited by drug resistance, posing a significant dilemma in clinical practice. Targeted protein degradation technologies, including proteolysis-targeting chimeras (PROTACs), have great potential in overcoming drug resistance and targeting undruggable targets. These areas of research are gaining increasing attention to various epigenetic related disease. In this review, we have provided a summary of the recently developed degraders targeting epigenetic readers, writers, and erasers. Additionally, we have outlined new applications for epigenetic protein degraders. Finally, we have addressed several unresolved challenges within the PROTAC field and offered potential solutions from our perspective. As the field continues to advance, the integration of these innovative methodologies holds great promise for addressing the challenges associated with PROTAC development.

摘要

表观遗传学是一个研究基因功能改变的领域,这种改变可以在DNA序列不变的情况下遗传,它涵盖了诸如组蛋白变体、氨基酸的翻译后修饰以及DNA碱基的共价修饰等分子途径。这些途径调节基因型向特定表型的转变。表观遗传学通过动态调节基因转录和确保基因组稳定性,在细胞生长、发育和分化中发挥着重要作用。这种调节由三个关键角色执行:写入者、读取者和擦除者。近年来,表观遗传蛋白在表观遗传调控中发挥了关键作用,并逐渐成为药物研发的重要靶点。靶向治疗是一种重要策略;然而,靶向药物的有效性常常受到耐药性的限制,这在临床实践中构成了重大困境。靶向蛋白质降解技术,包括蛋白酶靶向嵌合体(PROTACs),在克服耐药性和靶向不可成药靶点方面具有巨大潜力。这些研究领域越来越受到各种表观遗传相关疾病的关注。在这篇综述中,我们总结了最近开发的针对表观遗传读取者、写入者和擦除者的降解剂。此外,我们概述了表观遗传蛋白降解剂的新应用。最后,我们讨论了PROTAC领域内几个未解决的挑战,并从我们的角度提供了潜在的解决方案。随着该领域的不断发展,这些创新方法的整合有望解决与PROTAC开发相关的挑战。

相似文献

1
PROTACs Targeting Epigenetic Proteins.
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
2
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Molecules. 2023 Jan 26;28(3):1217. doi: 10.3390/molecules28031217.
3
Degraders in epigenetic therapy: PROTACs and beyond.
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
4
Recent advances in targeted protein degraders as potential therapeutic agents.
Mol Divers. 2024 Feb;28(1):309-333. doi: 10.1007/s11030-023-10606-w. Epub 2023 Feb 15.
5
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
BioDrugs. 2022 Sep;36(5):609-623. doi: 10.1007/s40259-022-00551-9. Epub 2022 Sep 13.
6
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Eur J Med Chem. 2020 Dec 1;207:112750. doi: 10.1016/j.ejmech.2020.112750. Epub 2020 Aug 18.
8
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
Bioorg Med Chem Lett. 2022 May 1;63:128653. doi: 10.1016/j.bmcl.2022.128653. Epub 2022 Mar 4.
10
Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Curr Opin Chem Biol. 2020 Aug;57:8-16. doi: 10.1016/j.cbpa.2020.01.010. Epub 2020 Mar 5.

引用本文的文献

3
Enhancing the Oral Bioavailability of Glutathione Using Innovative Analogue Approaches.
Pharmaceutics. 2025 Mar 18;17(3):385. doi: 10.3390/pharmaceutics17030385.
5
Degraders in epigenetic therapy: PROTACs and beyond.
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.

本文引用的文献

1
BRD4-targeting PROTAC as a unique tool to study biomolecular condensates.
Cell Discov. 2023 May 9;9(1):47. doi: 10.1038/s41421-023-00544-0.
2
Protein degraders enter the clinic - a new approach to cancer therapy.
Nat Rev Clin Oncol. 2023 Apr;20(4):265-278. doi: 10.1038/s41571-023-00736-3. Epub 2023 Feb 13.
3
Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
J Control Release. 2023 Feb;354:155-166. doi: 10.1016/j.jconrel.2022.12.035. Epub 2023 Jan 9.
4
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Nat Commun. 2022 Nov 10;13(1):6814. doi: 10.1038/s41467-022-34562-5.
5
Chemistries of bifunctional PROTAC degraders.
Chem Soc Rev. 2022 Aug 15;51(16):7066-7114. doi: 10.1039/d2cs00220e.
6
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
Signal Transduct Target Ther. 2022 Jun 9;7(1):181. doi: 10.1038/s41392-022-00999-9.
7
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC).
Chem Commun (Camb). 2022 Apr 7;58(29):4635-4638. doi: 10.1039/d2cc00272h.
9
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
Bioorg Med Chem Lett. 2022 May 1;63:128653. doi: 10.1016/j.bmcl.2022.128653. Epub 2022 Mar 4.
10
PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验